# Appendix A: Clinical Data Summary Tables

---

## A.1 LT3001 Clinical Trial Overview

| Trial ID | Phase | Region | Size | Window | Dose | Status |
|----------|-------|--------|------|--------|------|--------|
| LT3001-101 | Phase 1 | U.S. | ~20 | — | Dose escalation | Completed |
| LT3001-103 | Phase 1 | China | ~40 | — | Dose escalation | Completed |
| LT3001-105 | Phase 1 | U.S. | ~40 | — | Dose escalation | Completed |
| LT3001-201 | Phase 2 | U.S./Taiwan | ~20 | 4.5-24h | Multi-dose | Completed |
| **LT3001-202** | **Phase 2** | **China** | **301** | **4.5-24h** | **Multi-dose** | **Completed** |
| LT3001-203 | Phase 2 | U.S./Taiwan | 24 | 4.5-24h | 0.05 mg/kg | Ongoing (EVT combo) |
| **LT3001-205** | **Phase 2** | **Global** | **88** | **4.5-24h** | **Multi-dose** | **Completed** |
| LT3001-301 | Phase 3 | China | ~600 | 4.5-24h | 0.05 mg/kg | Starting 2026 |
| LT3001-302 | Phase 3 | Global | ~600 | 4.5-24h | 0.05 mg/kg | Expected 2027 |

---

## A.2 LT3001-202 Detailed Data

### A.2.1 Baseline Characteristics

| Item | Placebo (N=51) | Low Dose (N=49) | High Dose (N=99) | Highest Dose (N=98) |
|------|----------------|-----------------|-----------------|---------------------|
| Median age | 65 years | 64 years | 66 years | 65 years |
| Male proportion | 62% | 65% | 63% | 64% |
| Median NIHSS | 8 | 8 | 8 | 8 |
| Onset to treatment (hr) | 10.5 | 10.2 | 10.8 | 10.3 |

### A.2.2 Efficacy Results (90 Days)

| Endpoint | Placebo | Low Dose | **High Dose** | Highest Dose |
|----------|---------|----------|---------------|--------------|
| mRS 0-1 | 66.7% | 63.3% | **67.7%** | 65.3% |
| mRS 0-2 | 78.4% | 79.6% | **85.9%** | 82.7% |
| mRS 0-3 | 90.2% | 91.8% | 93.9% | 92.9% |

### A.2.3 Subgroup Analysis (High Dose vs Placebo)

| Subgroup | mRS 0-2 Placebo | mRS 0-2 High Dose | **Δ** |
|----------|-----------------|-------------------|-------|
| Overall | 78.4% | 85.9% | +7.5% |
| Moderate-Severe (NIHSS 7-10) | 73.2% | 82.5% | **+9.3%** |
| Disabling (Motor Deficit) | 65.0% | 78.0% | **+13.0%** |
| LAA (Large Artery Atherosclerosis) | 71.4% | 81.8% | **+10.4%** |

### A.2.4 Safety Data

| Metric | Placebo | High Dose | All Doses Combined |
|--------|---------|-----------|-------------------|
| Symptomatic ICH (sICH) | 0% | **0%** | **0% (0/297)** |
| Any ICH | 2.0% | 2.0% | 1.7% |
| Mortality (90 days) | 2.0% | 2.0% | 2.0% |
| Serious adverse events | 7.8% | 8.1% | 7.4% |

---

## A.3 LT3001-205 Detailed Data

| Endpoint | Placebo (N=44) | LT3001 (N=44) | Δ |
|----------|----------------|---------------|---|
| mRS 0-1 | 61.4% | 63.6% | +2.2% |
| mRS 0-2 | 75.0% | 81.8% | +6.8% |
| sICH | 0% | **0%** | — |

---

## A.4 Animal Study Data Summary

### A.4.1 Harvard/Tulane University Research

| Metric | tPA | LT3001 | Result |
|--------|-----|--------|--------|
| Infarct volume reduction | Baseline | **Superior** | LT3001 more effective |
| Hemorrhage incidence | Present | **Lower** | LT3001 safer |
| PAI-1 dependence | Yes | **No** | LT3001 mechanism independent |
| Neurological function score | Baseline | **Superior** | LT3001 better recovery |

### A.4.2 Key Finding

> *"The thrombolytic role of LT3001 might be independent of tPA and PAI-1 activity"*
>
> — Harvard/Tulane University, 2022

---

## A.5 Competitor Data Comparison

### A.5.1 JX10 Phase 2a (N=90)

| Endpoint | Placebo (N=38) | JX10 Combined (N=52) | Δ |
|----------|----------------|---------------------|---|
| mRS 0-1 | 18.4% | 40.4% | +22.0% |
| mRS 0-2 | 36.8% | 53.8% | +17.0% |
| sICH | 5.3% | 0% | — |

### A.5.2 Why Direct Comparison Is Invalid

| Factor | JX10 Phase 2a | LT3001-202 |
|--------|---------------|------------|
| Placebo mRS 0-2 | **36.8%** | **78.4%** |
| NIHSS lower limit | ≥6 | ≥4 |
| Mild patient proportion | 0% (excluded) | 25% |
| Gap reason | **Different enrollment severity** | — |

---

## A.6 tPA Historical Data Reference

### A.6.1 NINDS Trial (1995)

| Endpoint | Placebo | tPA | Δ |
|----------|---------|-----|---|
| mRS 0-1 (3 months) | 26% | 39% | +13% |
| sICH | 0.6% | **6.4%** | +5.8% |

### A.6.2 ECASS-3 Trial (2008)

| Endpoint | Placebo | tPA (3-4.5hr) | Δ |
|----------|---------|---------------|---|
| mRS 0-1 | 45.2% | 52.4% | +7.2% |
| sICH | 0.3% | **2.4%** | +2.1% |

---

## A.7 Key Data Quick Reference

| Metric | LT3001 | tPA | JX10 | TNKase |
|--------|--------|-----|------|--------|
| **sICH** | **0%** | 2-6% | 0% (N=52) | 2-3% |
| Time window | **24hr** | 4.5hr | 24hr | 4.5hr |
| mRS 0-2 Δ | +7.5% (overall) / +13% (disabling) | +7-13% | +17% | ~tPA |
| Phase 2 sample size | **297** | — | 52 | — |
| Administration | 6 doses / 3 days | 1-hour infusion | **Single injection** | **Single injection** |

---

**[Return to Chapter 10](-10_Investment_Thesis.md)** | **[Next Appendix: Appendix B — Competitor Comparison Matrix](-Appendix_B_Competitor_Matrix.md)**

---

*Data sources: Publicly available clinical trial results, academic publications*
